Expression of cell adhesion molecules and prognosis in breast cancer

British Journal of Surgery

Volumn 100, Issue 2, 2013, Pages 252-260

  Saadatmand, S ^a   De Kruijf, E M ^a   Sajet, A ^a   Dekker Ensink, N G ^a   Van Nes, J G H ^a   Putter, H ^a   Smit, V T H B M ^a   Van De Velde, C J H ^a   Liefers, G J ^a   Kuppen, P J K ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST TUMOR; FEMALE; FOLLOW UP; HUMAN; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PROGNOSIS;

ADULT; AGED; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CADHERINS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, DUCTAL, BREAST; CELL ADHESION MOLECULES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS;

EID: 84871319914     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.8980     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. de Boer M, van Dijck JA, Bult P, Borm GF, Tjan-Heijnen VC,. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst 2010; 102: 410-425.
3. Fidler IJ,. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-458.
4. Chiang AC, Massague J,. Molecular basis of metastasis. N Engl J Med 2008; 359: 2814-2823.
5. Gold P, Freedman SO,. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439-462.
6. Eskelinen M, Lipponen P, Syrjänen K,. Expression of tumour markers CA50, CEA and TPA in female breast carcinoma as related to histopathological findings and survival. Anticancer Res 1992; 12: 91-95.
7. Esteban JM, Felder B, Ahn C, Simpson JF, Battifora H, Shively JE,. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Cancer 1994; 74: 1575-1583.
8. Kuhajda FP, Offutt LE, Mendelsohn G,. The distribution of carcinoembryonic antigen in breast carcinoma. Diagnostic and prognostic implications. Cancer 1983; 52: 1257-1264.
9. Mansour EG, Hastert M, Park CH, Koehler KA, Petrelli M,. Tissue and plasma carcinoembryonic antigen in early breast cancer. A prognostic factor. Cancer 1983; 51: 1243-1248.
10. Mauri FA, Caffo O, Veronese S, Verderio P, Boracchi P, Bonzanini M, et al., Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma: an immunohistochemical study of clinical outcome in a series of 252 patients with long-term follow-up. Br J Cancer 1998; 77: 1661-1668.
11. Sundblad AS, Pellicer EM, Ricci L,. Carcinoembryonic antigen expression in stages I and II breast cancer: its relationship with clinicopathologic factors. Hum Pathol 1996; 27: 297-301.
12. Walker RA,. Demonstration of carcinoembryonic antigen in human breast carcinomas by the immunoperoxidase technique. J Clin Pathol 1980; 33: 356-360.
13. Baranwal S, Alahari SK,. Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem Biophys Res Commun 2009; 384: 6-11.
14. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR,. Cadherin switching. J Cell Sci 2008; 121: 727-735.
15. Agiostratidou G, Hulit J, Phillips GR, Hazan RB,. Differential cadherin expression: potential markers for epithelial to mesenchymal transformation during tumor progression. J Mammary Gland Biol Neoplasia 2007; 12: 127-133.
16. McSherry EA, Donatello S, Hopkins AM, McDonnell S,. Molecular basis of invasion in breast cancer. Cell Mol Life Sci 2007; 64: 3201-3218.
17. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, et al., E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113: 173-185.
18. Islam S, Carey TE, Wolf GT, Wheelock MJ, Johnson KR,. Expression of N-cadherin by human squamous carcinoma cells induces a scattered fibroblastic phenotype with disrupted cell-cell adhesion. J Cell Biol 1996; 135: 1643-1654.
19. Hazan RB, Kang L, Whooley BP, Borgen PI,. N-cadherin promotes adhesion between invasive breast cancer cells and the stroma. Cell Adhes Commun 1997; 4: 399-411.
20. Makrilia N, Kollias A, Manolopoulos L, Syrigos K,. Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest 2009; 27: 1023-1037.
21. Ruiz P, Gunthert U,. The cellular basis of metastasis. World J Urol 1996; 14: 141-150.
22. Obrink B,. Epithelial cell adhesion molecules. Exp Cell Res 1986; 163: 1-21.
23. Litvinov SV, Balzar M, Winter MJ, Bakker HA, Briaire-de Bruijn IH, Prins F, et al., Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 1997; 139: 1337-1348.
24. Winter MJ, Nagelkerken B, Mertens AE, Rees-Bakker HA, Briaire-de Bruijn IH, Litvinov SV,. Expression of Ep-CAM shifts the state of cadherin-mediated adhesions from strong to weak. Exp Cell Res 2003; 285: 50-58.
25. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G,. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000; 356: 1981-1982.
26. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, et al., High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004; 86: 207-213.
27. de Kruijf EM, van Nes JG, Sajet A, Tummers QR, Putter H, Osanto S, et al., The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 2010; 16: 1272-1280.
28. Putter H, Fiocco M, Geskus RB,. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007; 26: 2389-2430.
29. van Nes JG, de Kruijf EM, Faratian D, van de Velde CJ, Putter H, Falconer C, et al., COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 2011; 125: 671-685.
30. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW,. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008; 107: 309-330.
31. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al.,; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312.
32. Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, et al.,; TRANSBIG consortium. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 2006; 3: 540-551.
33. Thomassen M, Tan Q, Eiriksdottir F, Bak M, Cold S, Kruse TA,. Comparison of gene sets for expression profiling: prediction of metastasis from low-malignant breast cancer. Clin Cancer Res 2007; 13: 5355-5360.
34. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al., Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.
35. Slodkowska EA, Ross JS,. MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn 2009; 9: 417-422.
36. Schmitt M, Harbeck N, Brunner N, Janicke F, Meisner C, Muhlenweg B, et al., Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2011; 11: 617-634.
37. Yerushalmi R, Tyldesley S, Kennecke H, Speers C, Woods R, Knight B, et al., Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol 2012; 23: 338-345.